ACAD

Acadia Pharmaceuticals Inc.
CAPPED RATING

ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson\'s, Alzheimer\'s and schizophrenia.

Acadia Pharmaceuticals Inc. (ACAD) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (F). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.1 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
B
Factor Score 3.5 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 8.8
EV / EBITDA 17.2
Rev Growth YoY 22.8%
Gross Margin 63.9%
Price Return 3M -38.1%
Price Return 12M -21.0%
Catalyst Signal 0.00
Market Cap $3.2B
TTM Revenue $1.2B
Price / Sales 2.7
ROE 31.4%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.1) C (2.4) B (3.5) C- (2.0) F (0.0) C (2.2)
2026-11-10 B- (3.1) C (2.4) B (3.5) C- (1.9) F (0.0) C (2.2)
2026-11-03 C+ (2.8) C+ (2.7) B (3.5) C (2.2) F (0.0) C (2.2)
2026-10-27 B- (2.9) C+ (2.6) B (3.5) C- (2.1) F (0.0) C (2.2)
2026-10-20 B- (2.9) C+ (2.6) B (3.5) C+ (2.8) F (0.0) C (2.4)
Page 1 of 4